ClinicalTrials.gg
RecruitingNCT07708012Updated Oct 6, 2026

Clinical Study on Using Laparoscopic Sentinel Lymph Node Navigation Combined With Dual Endoscopy Surgery for Early Gastric Cancer

An interventional study of Combined double-scope surgery in Early-stage Upper Gastrointestinal Cancer, Stomach Cancer, Adenocarcinoma and Laparoscopy-assisted Surgery, sponsored by wangdongsheng. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Primary conditionStomach NeoplasmsRegistry: Gastrointestinal NeoplasmsReclassifiedWhy we changed it
Registry
Gastrointestinal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Stomach Neoplasms
Why
  1. The study's listed conditions name Stomach Neoplasms, a narrower term within Gastrointestinal Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by wangdongsheng · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2026, registered Jun 2026).
  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 6, 2026Now RecruitingSite recruiting status changed+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,187 studies in Stomach Neoplasms with a site in China — 483 open to participants now, 560 under way, 50 of them phase 3. Stomach Neoplasms · China.

Planned enrollment
858th of 884
9 · median 87
Started
2026
with 95 others
No phase
222 of 1,187
96 open now
Primary completion
2028-01
later than 448 of 559 live
Registered
1,145th of 1,187
by date

Among the 1,187 studies in Stomach Neoplasms with a site in China, this one is the 858th largest by planned enrollment of the 884 interventional ones that give a count, is one of 96 that started in 2026, is one of 222 with no phase, reaches primary completion later than 448 of the 559 other live ones, and was the 1,145th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

483 of the 1,187 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

478 more — sign in →

All 483 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,187 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

Gastric cancer is a common malignant tumour worldwide, and in China, the incidence and mortality rates of gastric cancer remain high. Standardised surgical treatment is effective, but the normal structure of the stomach undergoes irreversible changes, leading to a series of adverse reactions. At the same time, some early-stage gastric cancer patients cannot have the lesions completely removed endoscopically, and conventional surgery can affect postoperative normal life. Therefore, laparoscopic and endoscopic cooperative surgery has become a focus for precise stomach-preserving surgery. Participants meeting the surgical criteria are selected, and after discussing the treatment plan with their families and signing informed consent forms, relevant examinations are completed. During surgery, lesions are explored together using laparoscopy and endoscopy, then a fluorescent tracer is injected around the lesion and the lesion boundary is marked. Fifteen minutes after injecting the fluorescent tracer, the illuminated perigastric lymph nodes are the sentinel lymph node region (SLNB), and all fluorescent lymph nodes (sentinel lymph nodes) are removed and sent for intraoperative frozen pathology. If the SLNB is negative: a dual-endoscope combined local gastric resection (endoscope combined with laparoscopic local gastric resection or a modified procedure) is performed to completely remove the lesion, ensuring a negative margin. If the SLNB is positive: immediate conversion to laparoscopic-assisted radical gastrectomy (D2 lymph node dissection) is carried out. For SLNB-negative cases, the dual-endoscope combined local gastric resection specimen is placed in a retrieval bag for full removal and examination, with the stomach wall incision then closed by suturing or using a stapler. Postoperative follow-up includes monitoring tumour outcomes and quality of life.

Read the detailed description

Stomach cancer is one of the common malignant tumours worldwide, and in China, the incidence and mortality rates of stomach cancer remain high, posing a major public health burden. With the widespread implementation of stomach cancer screening in China, the detection rate of early-stage stomach cancer has significantly increased, now accounting for 19.5% of all stomach cancer cases. Early-stage stomach cancer (T1 stage) has a much better prognosis than advanced-stage cancer, with a 5-year survival rate exceeding 90% after standard treatment. Endoscopic submucosal dissection (ESD), due to its minimally invasive nature and ability to preserve stomach function, has become the standard treatment for certain cT1a-stage stomach cancers. However, for early-stage stomach cancer patients with a higher risk of lymph node metastasis, the lymph node metastasis rate can be close to 20%. In this context, if these patients only undergo endoscopic removal, they may face a higher risk of tumour residue. The traditional standard treatment is radical gastrectomy, usually combined with regional lymph node dissection (D1 or D2). Although this surgery is effective for cancer control, it can cause significant trauma, leading to irreversible changes to the patient's post-operative physiology and function, as well as long-term complications such as malnutrition, reflux oesophagitis and reduced quality of life, which have become key issues affecting the recovery of early-stage stomach cancer patients.

With the development of endoscopic technology (gastroscopy) and laparoscopic minimally invasive surgery, the concept of "function-preserving" surgery for early gastric cancer has been gaining increasing attention. This concept aims to minimise surgical trauma and preserve the anatomical structure and physiological function of the stomach while ensuring oncological safety. Achieving this goal relies heavily on the development and integration of two key techniques. First is Laparoscopic Sentinel Node Navigation Surgery (LSNNS). Sentinel lymph nodes are the first or group of lymph nodes along the primary tumour's lymphatic drainage pathway, and their pathological state is considered to highly predict metastasis in all lymph nodes in that region. In gastric cancer surgery, by injecting tracers (such as the fluorescent dye indocyanine green) under the mucosa around the tumour, and using the magnified view and fluorescence imaging system of laparoscopy, these sentinel lymph nodes can be located and removed in real time for intraoperative rapid pathological examination. The National Cancer Center in South Korea conducted a multicentre phase III randomised controlled clinical trial (SENORITA) on laparoscopic sentinel node navigation surgery for function-preserving surgery in early gastric cancer. In the LSNNS group, 210 patients (81%) underwent stomach-preserving surgery, and the results showed no significant difference in postoperative complication rates, 5-year local recurrence, disease-free survival (DFS), and overall survival (OS) compared to conventional laparoscopic radical gastrectomy. However, the LSNNS group had significantly better postoperative quality of life. These study results suggest that due to the complexity of gastric cancer lymphatic drainage and the skip and uncertain nature of metastasis, detecting the sentinel lymphatic basin (SLB) can provide a more comprehensive understanding of sentinel nodes, offering precise guidance for individualised lymph node dissection and avoiding unnecessary extended lymph node removal, reducing surgical trauma and related complications without compromising oncological outcomes.

Laparoscopic and endoscopic cooperative surgery (LECS) combines the advantages of laparoscopic internal view and operation with the precise localisation and removal capabilities of endoscopy. It's become a hot research topic in stomach-function-preserving surgery in recent years. Endoscopy provides a high-definition view of the mucosal surface from inside the cavity, allowing precise marking of tumour boundaries and submucosal dissection, while laparoscopy offers an external view of the serosal surface, enabling reliable full-thickness gastric wall resection, accurate suturing and regional lymph node inspection and management. Main LECS procedures include laparoscopic-assisted endoscopic full-thickness resection (LAEFR), endoscope-assisted wedge resection (EAWR), classic LECS and modified LECS. Several studies both domestic and international have shown LECS has advantages in treating various gastrointestinal tumours, but standardised procedures for early gastric cancer are not yet established, and current data is largely from retrospective studies, lacking high-quality prospective evidence.

03

Conditions studied

  • Early-stage Upper Gastrointestinal Cancer
  • Stomach Cancer, Adenocarcinoma
  • Laparoscopy-assisted Surgery
  • Endoscope

Browse trials for

04

In context

Stomach Neoplasms Reclassified

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

This study's planned enrollment of 9 is below the median of 66 across 2,505 interventional studies indexed under Stomach Neoplasms.

Browse Stomach Neoplasms studies →

Lead sponsor

This is the only study on the registry with wangdongsheng as lead sponsor.

Compared within Stomach Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Gastrointestinal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gastroscopy confirmed a solitary gastric adenocarcinoma;
  2. White light endoscopy, magnifying endoscopy-image-enhanced endoscopy,(ME-IEE), endoscopic ultrasound and enhanced CT comprehensively assessed as cT1N0M0, with no distant ;
  3. Assessed by MDT as unsuitable for simple ESD: including cases beyond the current guideline/consensus recommended ESD curative resection indications, or although at the endoscopic treatment border, significant fibrosis, scarring, non-lifting and other factors make complete endoscopic resection difficult and surgical function-preserving treatment has reasonable benefits;
  4. Lesion maximum diameter in principle ≤5 cm; for lesions close to 5 cm, near the cardia/pylorus or expected to cause stenosis or significant gastric deformation after local resection, they are listed as key review cases before surgery, and gastric preservation path can be directly abandoned during surgery;
  5. performance status score 0-1, able to tolerate general anaesthesia and laparoscopic surgery;
  6. Patient fully understands the potential benefits and uncertainties of SNNS/LECS, the possible false-negative risk of ICG single tracing and intraoperative pathology, as well as the possibility of conversion/additional standard radical gastrectomy, and has signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Preoperative imaging, endoscopy or MDT suggests cT2 or above, definite lymph node or distant metastasis;
  2. Pregnant or breastfeeding women;
  3. Previous major upper abdominal surgery leading to expected severe adhesions, significantly affecting SLB localisation or surgical implementation;
  4. Recurrent gastric cancer, multiple primary gastric cancers, or those who received preoperative radiotherapy and chemotherapy;
  5. Cases that have undergone ESD removal and achieved curative resection according to eCura standards;
  6. History of severe ICG allergy or deemed unsuitable by the researcher to use ICG;
  7. Patients with other untreated malignant tumours, severe cardiopulmonary dysfunction, or other conditions unable to tolerate general anaesthesia and pneumoperitoneum;
  8. Those unable to understand the study process or complete standard follow-up.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    Perform a combined surgery using both microscopes

    Procedure: Combined double-scope surgery

Interventions

  • ProcedureCombined double-scope surgery

    1. Inject the fluorescent dye under the endoscope to mark the lesion. 2. Remove the sentinel lymph node area highlighted by fluorescence after 15 minutes. 3. If no lymph node metastasis is found in the sentinel lymph node area (SLNB negative), perform a combined double-scope local gastrectomy (endoscopic combined with laparoscopic local gastrectomy or a modified procedure), completely remove the primary lesion, and ensure negative margins. 4. The local excision specimen should be fully spread and fixed within 20-30 minutes after removal, and sliced continuously at 2 mm intervals. The pathological report needs to include key information such as tissue type, depth of infiltration, margins and vascular invasion. 5. Postoperative patients are managed according to the standard postoperative pathway. Follow-ups are done at 1, 3, 6, 12, 24, and 36 months after surgery, and then annually, including physical exams, tumour marker tests, imaging checks, and quality of life questionnaires.

07

What researchers measure

Primary outcomes

  1. Postoperative complications within 30 days after surgery

    Time frame: Within 30 days after surgery

  2. Overall survival (OS)

    Time frame: 1 year and 3 years after surgery

  3. disease-free survival (DFS)

    Time frame: 1 year and 3 years after surgery

  4. Local recurrence rate (LR)

    Time frame: 1 year and 3 years after surgery

Secondary outcomes

  1. Sentinel lymph node prediction accuracy (sensitivity, specificity, etc.)

    Time frame: Up to two weeks after surgery (confirmed by paraffin pathology)

  2. Sentinel lymph node tracing success rate

    Time frame: At most, no more than 2 hours after receiving the specimen for frozen biopsy (intraoperative sentinel lymph node frozen pathology)

  3. R0 resection rate

    Time frame: Up to two weeks after surgery(confirmed by paraffin pathology)

  4. EORTC QLQ-C30/STO22 scale scores(European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30)

    Time frame: Before the surgery, and at 3, 6, 12 months after, and 2, 3 years post-surgery

  5. Weight and Body Mass Index

    Time frame: Before the surgery, and then 1, 3, 6, 12 months and 2, 3 years after

  6. Albumin and haemoglobin(g/L)

    Time frame: Before the surgery, and then 1, 3, 6, 12 months and 2, 3 years after

  7. NRS2002 Nutrition Risk Screening

    Time frame: Before the surgery, and then 1, 3, 6, 12 months and 2, 3 years after

08

Study locations

2 of 2 sites recruiting
  • Qingdao University Affiliated Hospital West Coast Campus
    Qingdao, Shandong 266000, China
    Enrolling by invitation
  • Gastrointestinal Surgery at Qingdao University Affiliated Hospital
    Qingdao, Shandong 266011, China
    Recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2028, 23 months after the start.

Of 358 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's planned 23 months is below that.

Counting every sponsor, half of 369 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2026
First posted
Jul 16, 2026
StartActual
Jan 8, 2026
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Recruiting
changed Oct 6, 2026
Sites
1 site added. Qingdao University Affiliated Hospital West Coast Campus is now Enrolling by invitation
Show site
  • Gastrointestinal Surgery at Qingdao University Affiliated Hospital · Qingdao, China
Oct 6, 2026
Start date
Jan 1, 2026→Jan 8, 2026
Oct 6, 2026
Enrollment
30→9
Oct 6, 2026
Eligibility
1 inclusion criterion edited, 5 added, 6 removed; 3 exclusion criteria edited, 4 added, 4 removed
What changed in the criteria
Inclusion criteria
  • RemovedAge 18-80, any gender;
  • RemovedGastric adenocarcinoma confirmed by gastroscopic biopsy, with a single lesion;
  • RemovedClinical staging cT1N0M0 based on enhanced CT, endoscopic ultrasound and other imaging evaluations (tumour limited to the mucosa or submucosa with no evidence of lymph node or distant metastasis);
  • RemovedAbsolute indications for endoscopic submucosal dissection (ESD), with lesions no larger than 5cm, or cases where endoscopic removal is difficult. Absolute indications for ESD (differentiated carcinoma, mucosal T1a stage, without ulcer ≤2 cm or with ulcer ≤3 cm; undifferentiated carcinoma without ulcer ≤2 cm. Difficult cases for endoscopic removal: negative "lifting sign", laterally spreading tumours and scar ulcers etc.);
  • RemovedMeets eCURA score criteria for non-curative ESD requiring additional surgery;
  • AddedGastroscopy biopsy confirmed a solitary gastric adenocarcinoma;
  • AddedWhite light endoscopy, magnifying endoscopy-image-enhanced endoscopy,(ME-IEE), endoscopic ultrasound and enhanced CT comprehensively assessed as cT1N0M0, with no distant metastasis;
  • AddedAssessed by MDT as unsuitable for simple ESD: including cases beyond the current guideline/consensus recommended ESD curative resection indications, or although at the endoscopic treatment border, significant fibrosis, scarring, non-lifting and other factors make complete endoscopic resection difficult and surgical function-preserving treatment has reasonable benefits;
  • AddedLesion maximum diameter in principle ≤5 cm; for lesions close to 5 cm, near the cardia/pylorus or expected to cause stenosis or significant gastric deformation after local resection, they are listed as key review cases before surgery, and gastric preservation path can be directly abandoned during surgery;
  • EditedECOG performance status score 0-1, able to tolerate general anaesthesia and laparoscopic surgery;
  • RemovedPatient fully informed and consents, signing the consent form. Note: For inclusion, meeting either criterion ④ or ⑤ is sufficient.
  • AddedPatient fully understands the potential benefits and uncertainties of SNNS/LECS, the possible false-negative risk of ICG single tracing and intraoperative pathology, as well as the possibility of conversion/additional standard radical gastrectomy, and has signed the informed consent form.
Exclusion criteria
  • AddedPreoperative imaging, endoscopy or MDT suggests cT2 or above, definite lymph node metastasis or distant metastasis;
  • ChangedBefore Those with a history of major upper abdominal surgery where severe abdominal adhesions are expected;Now Previous major upper abdominal surgery leading to expected severe adhesions, significantly affecting SLB localisation or surgical implementation;
  • EditedPatients with recurrentRecurrent gastric cancer, multiple primary tumoursgastric cancers, or those who have undergonereceived preoperative chemoradiotherapyradiotherapy and chemotherapy;
  • EditedThose meetingCases that have undergone ESD indicationsremoval and having completedachieved curative endoscopic resection according to eCURAeCura standards [12,13];
  • RemovedPatients with other unresectable malignant tumours;
  • RemovedThose with severe heart, lung, liver, or kidney dysfunction who cannot tolerate general anaesthesia and surgery;
  • RemovedThose allergic to indocyanine green (ICG) or nano carbon tracers;
  • RemovedThose with mental illness who cannot cooperate with the study and follow-up.
  • AddedHistory of severe ICG allergy or deemed unsuitable by the researcher to use ICG;
  • AddedPatients with other untreated malignant tumours, severe cardiopulmonary dysfunction, or other conditions unable to tolerate general anaesthesia and pneumoperitoneum;
  • AddedThose unable to understand the study process or complete standard follow-up.
Oct 6, 2026
Interventions
Changed Combined binocular surgery→Combined double-scope surgery
Oct 6, 2026
Contact
Study contact now listed: added w•••@qdu.edu.cn · •••7896. See the current contact
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Enrolling by invitation→Recruiting
    1 site added. Qingdao University Affiliated Hospital West Coast Campus is now Enrolling by invitation
    Show site
    • Gastrointestinal Surgery at Qingdao University Affiliated Hospital · Qingdao, China
    Start date Jan 1, 2026→Jan 8, 2026
    Enrollment 30→9
    Eligibility 1 inclusion criterion edited, 5 added, 6 removed; 3 exclusion criteria edited, 4 added, 4 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedAge 18-80, any gender;
    • RemovedGastric adenocarcinoma confirmed by gastroscopic biopsy, with a single lesion;
    • RemovedClinical staging cT1N0M0 based on enhanced CT, endoscopic ultrasound and other imaging evaluations (tumour limited to the mucosa or submucosa with no evidence of lymph node or distant metastasis);
    • RemovedAbsolute indications for endoscopic submucosal dissection (ESD), with lesions no larger than 5cm, or cases where endoscopic removal is difficult. Absolute indications for ESD (differentiated carcinoma, mucosal T1a stage, without ulcer ≤2 cm or with ulcer ≤3 cm; undifferentiated carcinoma without ulcer ≤2 cm. Difficult cases for endoscopic removal: negative "lifting sign", laterally spreading tumours and scar ulcers etc.);
    • RemovedMeets eCURA score criteria for non-curative ESD requiring additional surgery;
    • AddedGastroscopy biopsy confirmed a solitary gastric adenocarcinoma;
    • AddedWhite light endoscopy, magnifying endoscopy-image-enhanced endoscopy,(ME-IEE), endoscopic ultrasound and enhanced CT comprehensively assessed as cT1N0M0, with no distant metastasis;
    • AddedAssessed by MDT as unsuitable for simple ESD: including cases beyond the current guideline/consensus recommended ESD curative resection indications, or although at the endoscopic treatment border, significant fibrosis, scarring, non-lifting and other factors make complete endoscopic resection difficult and surgical function-preserving treatment has reasonable benefits;
    • AddedLesion maximum diameter in principle ≤5 cm; for lesions close to 5 cm, near the cardia/pylorus or expected to cause stenosis or significant gastric deformation after local resection, they are listed as key review cases before surgery, and gastric preservation path can be directly abandoned during surgery;
    • EditedECOG performance status score 0-1, able to tolerate general anaesthesia and laparoscopic surgery;
    • RemovedPatient fully informed and consents, signing the consent form. Note: For inclusion, meeting either criterion ④ or ⑤ is sufficient.
    • AddedPatient fully understands the potential benefits and uncertainties of SNNS/LECS, the possible false-negative risk of ICG single tracing and intraoperative pathology, as well as the possibility of conversion/additional standard radical gastrectomy, and has signed the informed consent form.
    Exclusion criteria
    • AddedPreoperative imaging, endoscopy or MDT suggests cT2 or above, definite lymph node metastasis or distant metastasis;
    • ChangedBefore Those with a history of major upper abdominal surgery where severe abdominal adhesions are expected;Now Previous major upper abdominal surgery leading to expected severe adhesions, significantly affecting SLB localisation or surgical implementation;
    • EditedPatients with recurrentRecurrent gastric cancer, multiple primary tumoursgastric cancers, or those who have undergonereceived preoperative chemoradiotherapyradiotherapy and chemotherapy;
    • EditedThose meetingCases that have undergone ESD indicationsremoval and having completedachieved curative endoscopic resection according to eCURAeCura standards [12,13];
    • RemovedPatients with other unresectable malignant tumours;
    • RemovedThose with severe heart, lung, liver, or kidney dysfunction who cannot tolerate general anaesthesia and surgery;
    • RemovedThose allergic to indocyanine green (ICG) or nano carbon tracers;
    • RemovedThose with mental illness who cannot cooperate with the study and follow-up.
    • AddedHistory of severe ICG allergy or deemed unsuitable by the researcher to use ICG;
    • AddedPatients with other untreated malignant tumours, severe cardiopulmonary dysfunction, or other conditions unable to tolerate general anaesthesia and pneumoperitoneum;
    • AddedThose unable to understand the study process or complete standard follow-up.
    Interventions Changed Combined binocular surgery→Combined double-scope surgery
    Contact Study contact now listed: added w•••@qdu.edu.cn · •••7896. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07708012
Lead sponsor
wangdongsheng
Responsible party
wangdongsheng (Chief Physician, The Affiliated Hospital of Qingdao University) — Sponsor-investigator
First posted
Jul 16, 2026
Start date
Jan 8, 2026
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

dongsheng wang Dr wang
Contact
wangdongsheng@qdu.edu.cn
+86 18661807896

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion